{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-068108","form_type":"8-K","ticker":"TVRD","cik":"0001346830","company_name":"Tvardi Therapeutics, Inc.","filed_at":"2022-06-03T23:59:59+00:00","discovered_at":"2026-05-14T18:04:00.329672+00:00","generated_at":"2026-06-25T04:39:07.383580+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"negative","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Cara Therapeutics CFO Thomas Reilly resigns; Richard Makara named interim CFO","bullets":["Thomas Reilly resigns as CFO effective June 15, 2022 to pursue a new opportunity.","Departure is not due to any dispute or disagreement with the company.","Richard Makara, VP Head of Accounting & Controller, assumes interim CFO role.","Makara receives 7,500 RSUs vesting at earlier of Dec 31, 2022 or new CFO appointment.","Makara previously served as interim CFO from Dec 2019 to Oct 2020."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-068108","json":"https://secwatch.observer/filing/0001104659-22-068108.json","markdown":"https://secwatch.observer/filing/0001104659-22-068108.md","text":"https://secwatch.observer/filing/0001104659-22-068108.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1346830/000110465922068108/0001104659-22-068108-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1346830/000110465922068108/tm2217665d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T04:39:07.383580+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5aecc5db15","claim":"Richard Makara was appointed as Interim Chief Financial Officer at Tvardi Therapeutics, Inc..","evidence_excerpt":"Effective immediately following Mr. Reilly’s departure, Richard Makara, the Company’s Vice President, Head of Accounting & Controller, will assume Mr. Reilly’s responsibilities on an interim basis.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1346830/000110465922068108/0001104659-22-068108-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Interim Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"fc0201ffe7","claim":"Thomas Reilly resigned as Chief Financial Officer at Tvardi Therapeutics, Inc..","evidence_excerpt":"On May 27, 2022, Thomas Reilly, Chief Financial Officer of Cara Therapeutics, Inc. (the “Company”), gave notice of his resignation, effective on or about June 15, 2022, to pursue a new opportunity.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1346830/000110465922068108/0001104659-22-068108-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}